On February 27, 2023, the U.S. Food and Drug Administration (FDA) issued a warning letter to medical professionals concerning the potential risk of early structural valve deterioration (SVD) with Abbott Trifecta valves. The affected valves include Abbott’s standard Trifecta valves and its Trifecta valves with Glide Technology (GT). The issue involves a higher accumulative incidence of early structural valve deterioration (SVD) for Trifecta valves compared to other surgical bioprosthetic valves.

The FDA stated in the warning letter to healthcare providers that it received adverse incident reports describing early structural valve deterioration. The FDA is currently working with Abbott to assess all available information. The FDA is encouraging patients and doctors to report all adverse events connected with the affected Trifecta valves. The FDA also stated that fast reporting of any adverse events helps the FDA determine and better comprehend the safety risks associated with surgical bioprosthetic valves.

To minimize the risk of early structural valve deterioration (SVD) with Trifecta valves, healthcare providers should be aware of current patient management considerations, as communicated by Abbott. When discussing treatment options with patients and their caregivers, all available aortic valve treatment options should be reviewed to make a shared clinical decision before surgery. If a Trifecta GT valve is chosen, the Instructions for Use (IFU) should be read and carefully followed during implantation.

After implantation, patients who have received a Trifecta valve should be monitored for signs and symptoms of potential SVD, and if new symptoms such as shortness of breath or fatigue occur, patients should be instructed to seek medical attention. Lifelong follow-up visits should be scheduled at least yearly, including a transthoracic echocardiogram (TTE) assessment of the valve starting one-year post-implantation. Any adverse events related to Trifecta valves should be reported to the FDA by referring to the Reporting Problems to the FDA section below.

The affected Abbott Trifecta and Trifecta GT valves are replacement heart valve devices that treat damaged, diseased, or malfunctioning prosthetic or native aortic heart valves. Abbott’s first-generation Trifecta valve was first approved in 2011, but the medical device is no longer being marketed in the United States. The FDA approved Abbott’s Trifecta GT valve in 2016.

The FDA routinely monitors the safety and effectiveness of medical devices by evaluating adverse event reports and published literature. Published studies have compared the durability of Trifecta valves to other commercially available bovine pericardial valves at various time points post-implant. These studies have indicated a higher incidence of early SVD and lower freedom from reintervention due to SVD associated with Trifecta valves.

The published literature includes results for both Trifecta and Trifecta GT valves, and patient management considerations provided by Abbott apply to both models. Healthcare providers should be aware of these findings when considering Trifecta valves for their patients and should take appropriate measures to minimize the risk of SVD.

The FDA has received medical device reports (MDRs) that detail instances of early structural valve deterioration (SVD) with Trifecta valves. These reports have indicated that the peak time for SVD occurs three to four years post-implant and that outcomes have included surgical valve explant/replacement, transcatheter valve-in-valve intervention, and, in some cases, death.

While the FDA recognizes the limitations of MDR data, including the inability to determine incidence from passive surveillance reporting systems, it is one source of information used by the agency to monitor the safety of medical devices. Healthcare providers should take note of these reports and implement appropriate measures to monitor patients who have received Trifecta valves for signs and symptoms of potential SVD. If any adverse events occur, they should be promptly reported to the FDA.

The FDA is collaborating with the manufacturer to thoroughly evaluate the issue related to early SVD with Trifecta valves and will develop additional patient management strategies, if necessary. The FDA will continue to monitor literature and reports of adverse events related to Trifecta valves to ensure patient safety. The FDA will promptly inform the public if any significant new information or recommendations become available. Healthcare providers should stay informed about any updates and adjust their patient management strategies accordingly.

Contact Parker Waichman LLP For A Free Case Review

If you lost a loved one suffered harm due to a defective Abbott Trifecta Valve, you have the right to seek justice and compensation for your losses. The national product liability attorneys at Parker Waichman LLP are here to help you understand your legal options and file your defective medical device lawsuit, if qualified.

The statute of limitations for filing a lawsuit is limited by law. Call Parker Waichman LLP today at 800-968-7529 to schedule a free, no-obligation consultation with one of our national product liability attorneys. Our toll-free number is available 24/7, so you can call us anytime, day or night. We are here to answer your questions, listen to your concerns, and help your family receive justice and financial compensation.

SHARE:
Free Consultation

Parker Waichman LLP

Untitled(Required)

Parker Waichman Reviews

4.8 from 549 Reviews

Related Testimonials

Our law firm is ready to represent you in your injury case. We’ve helped many New York residents as well as those needing help nationwide. Contact our team for a free case consultation today.

I had a great experience with them , everyone was very helpful and sweet.

Michelle Murphy

4 months ago

Zarahi was very professional and very Quick and very knowledgeable i realy appreciated her patience and perseverance she Deserves 100 stars 🌟 but since i can only send 5 i Guess i will just have to send that truly yours Rashine Downs

Kush Three

6 months ago

VERY NICE WORK PLACE THEY HAVE BEEN GOOD TO MY MOM

Whitney Brinson

5 years ago

They treated me with tender love and care

Terrell Weaver

2 months ago

Wonderful people. They made the whole process if dealing with a gov’t agency so easy. Special compliments to Gina Viti

Michael Ross

2 months ago

I’m a 9/11 first responder, and I can honestly say that Parker Waichman made me feel like they had my best interest in my VCF case. Ms Candalino & Ms Viti are top notch in my book. I was constantly informed on the status of my case. I would definitely recommend Parker Waichman LLP to family and friends.

D D

6 years ago

We Have Many Locations To Serve You
Serving Mass Tort Clients Nationally

We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.

Long Island - Nassau

Parker Waichman LLP

6 Harbor Park Drive

Port Washington, NY 11050

(516) 466-6500

Long Island – Suffolk

Parker Waichman LLP

201 Old Country Road – Suite 145

Melville, NY 11747

(631) 390-0800

New York City

Parker Waichman LLP

59 Maiden Lane, 6th Floor

New York, NY 10038

(212) 267-6700

Queens

Parker Waichman LLP

118-35 Queens Boulevard, Suite 400

Forest Hills, NY 11375

(718) 469-6900

Brooklyn

Parker Waichman LLP

300 Cadman Plaza West

One Pierrepont Plaza, 12th Floor

Brooklyn, NY 11201

(718) 554-8055

Florida

Parker Waichman LLP

27299 Riverview Center Boulevard, Suite 108

Bonita Springs, FL 34134

(239) 390-1000

New Jersey

Parker Waichman LLP

80 Main Street, Suite 265

West Orange, NJ 07052

(973) 323-3603
Nationwide Service

We handle mass torts cases nationwide. Please contact our office to learn more.